MRI Clinical Trial
— EIROSOfficial title:
Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)
NCT number | NCT03333447 |
Other study ID # | C1294 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 17, 2017 |
Est. completion date | December 27, 2018 |
Verified date | June 2021 |
Source | CEN Biotech |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study with standardized reading MRIs, will provide for the first time objective and quantified data on organomegaly (liver and spleen volumes) as well as bone alteration (Bone Marrow Burden11) of French patients treated with VPRIV®. These data will help to better assess the impact of this treatment on these parameters. The result of this study will also answer in part to the request of the French Transparency Commission (CT: Commission de Transparence) of the French National Health Authority to provide them with data of French patients treated with VPRIV®.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 27, 2018 |
Est. primary completion date | September 13, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: 1. Patients of any age or gender with confirmed diagnosis of type 1 Gaucher disease, 2. Patients treated with VPRIV® at the beginning of the study. Prior starting VPRIV® patients could be either treatment naïve or previously treated with any other Gaucher treatment than VPRIV® 3. Patients should have one MRI data in the 5 previous years before starting VPRIV® Treatment (up to 3 months after initiation of VPRIV® 4. Informed written consent obtained from the patient, and/or patient's parent(s), and/or legal representative. Assent, if old enough to grant, will be obtained from all patients under the age of 18 years Exclusion Criteria: 1. Patients for whom MRI is contra-indicated 2. Patients who did not had an MRI during the five years prior to the initiation of treatment with VPRIV® or within three months after initiation of VPRIV®. 3. Patients included in an ongoing clinical trial where the product is blinded |
Country | Name | City | State |
---|---|---|---|
France | Beaujon Hospital | Clichy |
Lead Sponsor | Collaborator |
---|---|
CEN Biotech | BioClinica, Inc., Takeda |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change over time between the baseline MRI and the follow-up MRIs, of the BMB score weighted at T1 measured at the femur. | To describe changes in bone disease in femur in Gaucher's disease patients treated with Velaglucerase alfa measured by MRI. The primary endpoint is the change over time between the baseline MRI and the follow-up MRIs, of the BMB score weighted at T1 measured at the femur. | 2 YEARS | |
Primary | The change over time between the baseline MRI and the follow-up MRIs, of the BMB score weighted at T2 measured at the femur. | To describe changes in bone disease in femur in Gaucher's disease patients treated with Velaglucerase alfa measured by MRI. The primary endpoint is the change over time between the baseline MRI and the follow-up MRIs, of the BMB score weighted at T2 measured at the femur. | 2 YEARS | |
Primary | The change over time between the baseline MRI and the follow-up MRIs, of the BMB score weighted at T1 measured at the lumbar spine. | To describe changes in bone disease in lumbar spine in Gaucher's disease patients treated with Velaglucerase alfa measured by MRI. The primary endpoint is the change over time between the baseline MRI and the follow-up MRIs, of the BMB score weighted at T1 measured at the lumbar spine. | 2 YEARS | |
Primary | The change over time between the baseline MRI and the follow-up MRIs, of the BMB score weighted at T2 measured at the lumbar spine. | To describe changes in bone disease in lumbar spine in Gaucher's disease patients treated with Velaglucerase alfa measured by MRI. The primary endpoint is the change over time between the baseline MRI and the follow-up MRIs, of the BMB score weighted at T2 measured at the lumbar spine. | 2 YEARS | |
Secondary | Describe socio-demographic characteristics of patients : age | To describe the socio-demographic of patients : age | 2 YEARS | |
Secondary | Describe socio-demographic characteristics of patients : sex | To describe the socio-demographic of patients : sex | 2 YEARS | |
Secondary | Describe socio-demographic characteristics of patients : occupation | To describe the socio-demographic of patients : occupation | 2 YEARS | |
Secondary | Clinical evolution of patients :weight (kg) | To describe the clinical evolution of patients : weight (kg) | 2 YEARS | |
Secondary | Clinical evolution of patients : height (cm) | To describe the clinical evolution of patients : height (cm) | 2 YEARS | |
Secondary | Clinical evolution of patients : absence or presence (mild, moderate or severe) asthenia | To describe the clinical evolution of patients : absence or presence (mild, moderate or severe) asthenia | 2 YEARS | |
Secondary | Clinical evolution of patients : abdominal pain | To describe the clinical evolution of patients : abdominal pain | 2 YEARS | |
Secondary | Clinical evolution of patients : chronic bone pain | To describe the clinical evolution of patients : chronic bone pain | 2 YEARS | |
Secondary | Clinical evolution of patients : bone crises | To describe the clinical evolution of patients : bone crises | 2 YEARS | |
Secondary | Clinical evolution of patients : bleeding and hemorrhagic syndrome | To describe the clinical evolution of patients : bleeding and hemorrhagic syndrome | 2 YEARS | |
Secondary | Clinical evolution of patients : pulmonary impairment | To describe the clinical evolution of patients : pulmonary impairment | 2 YEARS | |
Secondary | Clinical evolution of patients : neurological impairment | To describe the clinical evolution of patients : neurological impairment | 2 YEARS | |
Secondary | Clinical evolution of patient : absence or presence of hepatomegaly | To describe the clinical evolution of patients : absence or presence of hepatomegaly, with the extent of the arrow (medio-clavicular line) (cm) | 2 YEARS | |
Secondary | Clinical evolution of patients : absence or presence of splenomegaly | To describe the clinical evolution of patients : absence or presence of splenomegaly, with the extent of the costal overhang (cm) | 2 YEARS | |
Secondary | Evolution of the parameters measured by MRI : Bone alterations | To describe the evolution of the parameters measured by MRI : bone alterations (spine, pelvis, femurs, tibias and other symptomatic localization). Absence or presence of bone lesions and their locations: bone infiltration, cortical thinning, osteonecrosis, bone infarction, stroke sequelae, vertebral compression, fracture or other bone disease.
If possible, compare the evolution of MRI parameters between treatment-naive patients and patients previously treated with another specific treatment for Gaucher disease at the baseline MRI. |
2 YEARS | |
Secondary | Evolution of the parameters measured by MRI : Liver evaluation : absence or presence of hepatomegaly with the extent of the arrow (medio-clavicular line) (cm). | To describe the evolution of the parameters measured by MRI : Visceral involvement : Liver evaluation criteria MRI : absence or presence of hepatomegaly, with the extent of the arrow (medio-clavicular line) (cm).
If possible, compare the evolution of this MRI parameters between treatment-naive patients and patients previously treated with another specific treatment for Gaucher disease at the baseline MRI. |
2 YEARS | |
Secondary | Evolution of the parameters measured by MRI : Liver evaluation : evolution of the liver volume (m3). | To describe the evolution of the parameters measured by MRI : Liver evaluation criteria MRI : evolution of the liver volume (m3).
If possible, compare the evolution of this MRI parameters between treatment-naive patients and patients previously treated with another specific treatment for Gaucher disease at the baseline MRI. |
2 YEARS | |
Secondary | Evolution of the parameters measured by MRI : Spleen evaluation : absence or presence of splenomegaly | To describe the evolution of the parameters measured by MRI : Spleen evaluation MRI : absence or presence of splenomegaly.
If possible, compare the evolution of this MRI parameters between treatment-naive patients and patients previously treated with another specific treatment for Gaucher disease at the baseline MRI. |
2 YEARS | |
Secondary | Evolution of the parameters measured by MRI : Spleen evaluation : evolution of the extent of the costal overhang (cm) | To describe the evolution of the parameters measured by MRI : Spleen evaluation MRI : evolution of the extent of the costal overhang (cm).
If possible, compare the evolution of this MRI parameters between treatment-naive patients and patients previously treated with another specific treatment for Gaucher disease at the baseline MRI. |
2 YEARS | |
Secondary | Evolution of the parameters measured by MRI : Spleen evaluation : absence or presence of splenomegaly. | To describe the evolution of the parameters measured by MRI : Spleen evaluation MRI : absence or presence of splenomegaly.
If possible, compare the evolution of this MRI parameters between treatment-naive patients and patients previously treated with another specific treatment for Gaucher disease at the baseline MRI. |
2 YEARS | |
Secondary | Evolution of the parameters measured by MRI : Spleen evaluation : evolution of the spleen volume (m3) | To describe the evolution of the parameters measured by MRI : Spleen evaluation MRI : evolution of the spleen volume (m3).
If possible, compare the evolution of this MRI parameters between treatment-naive patients and patients previously treated with another specific treatment for Gaucher disease at the baseline MRI. |
2 YEARS | |
Secondary | Evolution of the parameters measured by MRI : Presence or absence of myocardia alterations | To describe the evolution of the parameters measured by MRI : Presence or absence of myocardial, nodules, fibrosis, vesicular stones or other alterations.
If possible, compare the evolution of MRI parameters between treatment-naive patients and patients previously treated with another specific treatment for Gaucher disease at the baseline MRI. |
2 YEARS | |
Secondary | Evolution of Biological parameters : hemoglobin (g/dl) | To describe the evolution of biological parameters : hemoglobin (g/dl) | 2 YEARS | |
Secondary | Evolution of Biological parameters : leukocytes (cells/mm3) | To describe the evolution of biological parameters : leukocytes (cells/mm3) | 2 YEARS | |
Secondary | Evolution of Biological parameters : platelets (mm3) | To describe the evolution of biological parameters : platelets (mm3) | 2 YEARS | |
Secondary | Evolution of Biological parameters : Angiotensin Converting Enzyme (ACE) (U/l) | To describe the evolution of biological parameters : ACE (angiotensin converting enzyme (U/l) | 2 YEARS | |
Secondary | Evolution of Biological parameters: ferritin (mg/l) | To describe the evolution of biological parameters : ferritin (mg/l) | 2 YEARS | |
Secondary | Evolution of Biological parameters : chitotriosidase (nmol/h/ml) | To describe the evolution of biological parameters : chitotriosidase (nmol/h/ml) | 2 YEARS | |
Secondary | Evolution of Biological parameters : CCL18 (ng/ml) | To describe the evolution of biological parameters : CCL18 (ng/ml) | 2 YEARS | |
Secondary | Evolution of Biological parameters : vitamin D (nmol/L) | To describe the evolution of biological parameters : vitamin D (nmol/L) | 2 YEARS | |
Secondary | Evolution of Biological parameters : vitamin B12 (pmol/l) | To describe the evolution of biological parameters : vitamin B12 (pmol/l) | 2 YEARS | |
Secondary | Evolution of Biological parameters : serum glutamate oxaloacetate transaminase (SGOT) (U/l) | To describe the evolution of biological parameters : SGOT (U/l) | 2 YEARS | |
Secondary | Evolution of Biological parameters : Aspartate aminotransferase (AST) (U/l) | To describe the evolution of biological parameters : AST (U/l) | 2 YEARS | |
Secondary | Evolution of Biological parameters : serum glutamate pyruvate transaminase (SGPT) (U/l) | To describe the evolution of biological parameters : SGPT (U/l) | 2 YEARS | |
Secondary | Evolution of Biological parameters : Alanine Aminotransferase (ALT) (U/l) | To describe the evolution of biological parameters : ALT (U/l) | 2 YEARS | |
Secondary | Evolution of Biological parameters : Gamma-glutamyltransferase (GGT) (U/l) | To describe the evolution of biological parameters : GGT (U/l) | 2 YEARS | |
Secondary | Evolution of Biological parameters : alkaline phosphatase (U/l) | To describe the evolution of biological parameters : alkaline phosphatase (U/l) | 2 YEARS | |
Secondary | Evolution of Biological parameters : triglycerides (mmol/l) | To describe the evolution of biological parameters : triglycerides (mmol/l) | 2 YEARS | |
Secondary | Evolution of Biological parameters : total cholesterol (mmol/l) | To describe the evolution of biological parameters : total cholesterol (mmol/l) | 2 YEARS | |
Secondary | Evolution of Biological parameters : gamma globulin (g/l) | To describe the evolution of biological parameters : gamma globulin (g/l). | 2 YEARS | |
Secondary | Evolution of Biological parameters : serum calcium (mmol/l) | To describe the evolution of biological parameters : serum calcium (mmol/l) | 2 YEARS | |
Secondary | Evolution of Biological parameters : presence or absence of a monoclonal peak and the type if any. | To describe the evolution of biological parameters : presence or absence of a monoclonal peak and the type if any. | 2 YEARS |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05036629 -
Development of MRI Protocols and Associated Neuro-physiological Explorations in Healthy and Pathological Subjects
|
N/A | |
Completed |
NCT02548819 -
University Hospital Cardiac Device MR Registry: The Safety of MR Imaging in Patients With Implanted Cardiac Devices
|
N/A | |
Completed |
NCT01168479 -
FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer
|
Phase 3 | |
Completed |
NCT00512226 -
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
|
N/A | |
Recruiting |
NCT05439330 -
Application of a Dental-dedicated MRI in the Diagnosis of Temporomandibular Joint Disorders, Tissue Alterations Related to Third Molars, Periapical and Periodontal Inflammatory Diseases, and Implant Treatment Planning
|
N/A | |
Not yet recruiting |
NCT05464576 -
Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic Analysis
|
N/A | |
Recruiting |
NCT04034667 -
Study of CT and MR in the Lung Cancer
|
||
Recruiting |
NCT04028375 -
Study of CT and MR in the Gastric Cancer
|
||
Recruiting |
NCT04231175 -
Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal Cancer
|
N/A | |
Completed |
NCT00949507 -
Comparison of Two Regimens of Anesthesia for Children Undergoing Magnetic Resonance Imaging (MRI) in General Anesthesia
|
Phase 4 | |
Completed |
NCT01420211 -
Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist®
|
Phase 1/Phase 2 | |
Recruiting |
NCT05167669 -
Pain Relief in Symptomatic Bone Metastases With Adjuvant Hyperthermia MR Guided HIFU
|
Early Phase 1 | |
Recruiting |
NCT05618990 -
OPTIMIZATION of ADVANCED MR SEQUENCES
|
||
Recruiting |
NCT05107232 -
OSV-IRM - Volunteer MRI Sequence Optimization
|
N/A | |
Completed |
NCT00556101 -
Patient Acceptance of Whole Body Magnetic Resonance Angiography
|
N/A | |
Recruiting |
NCT03142698 -
Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis
|
N/A | |
Suspended |
NCT00554073 -
Whole Body Magnetic Resonance Angiography in Ischemic Patients at 1.5 and 3T
|
N/A | |
Completed |
NCT06366906 -
10-year Retrospective Study of Oral and Maxillofacial Squamous Cell Carcinoma
|
||
Not yet recruiting |
NCT05359497 -
Value of MRCP+ And Liver Multiscan in the Management of Dominant Strictures in Primary Sclerosing Cholangitis
|
N/A | |
Recruiting |
NCT05192629 -
Intranasal Dexmedetomidine Versus Oral Midazolam as Premedication for Propofol Sedation in Pediatric Patients Undergoing Magnetic Resonance Imaging
|
Phase 3 |